Yamaguchi Tetsuo, Miyamoto Takamichi, Iwai Takamasa, Yamaguchi Junji, Hijikata Sadahiro, Miyazaki Ryoichi, Miwa Naoyuki, Sekigawa Masahiro, Hara Nobuhiro, Nagata Yasutoshi, Nozato Toshihiro, Yamauchi Yasuteru, Obayashi Toru, Isobe Mitsuaki
Department of Cardiology, Japanese Red Cross Musashino Hospital, Tokyo, Japan; Department of Cardiology, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
Department of Cardiology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
J Cardiol. 2017 Jul;70(1):18-22. doi: 10.1016/j.jjcc.2016.09.009. Epub 2016 Oct 15.
The prognosis of super-elderly patients (age≥85 years) who undergo bradycardia pacemaker (PM) implantation remains unknown.
We retrospectively enrolled 868 patients (men 49.0%, 76.6±10.6 years) who could walk unassisted and whose expected life expectancy was more than 1 year, receiving their first bradycardia PM implantation between January 1, 2006, and June 30, 2013. Clinical outcomes were compared between super-elderly patients (n=201, mean age 88.6±3.2 years) and younger patients (n=667, 73.0±9.3 years).
At the end of a median 1285-day follow-up, 128 patients (14.7%) died, of which 54 were cardiac deaths (42.2%). Mortality rates were similar between the groups (16.4% vs. 14.2%, log-rank p=0.56) and across different indications for implantation (atrio-ventricular conduction disturbance or sick sinus syndrome, p=0.59), initial rhythms (sinus rhythm or persistent atrial fibrillation, p=0.62), pacing modes (dual chamber pacing or VVI pacing, p=0.26), and ventricular lead positions (septum or apex, p=0.52). On Cox proportional hazard model analysis, hypertension [hazard ratio (HR)=1.74, 95% confidence interval (CI)=1.19-2.54, p=0.004], diabetes mellitus (HR=2.18, 95% CI=1.51-3.14, p<0.001), history of myocardial infarction (HR=3.59, 95% CI=2.49-5.16, p<0.001), and history of stroke (HR=2.26, 95% CI=1.51-3.37, p<0.001) were independent predictors for mortality.
The mortality rate of super-elderly patients who had no critical illnesses and were healthy enough to walk unassisted at the time of PM implantation was not inferior to that of younger patients. Prognosis was determined by comorbidities, but not by age, PM indication, initial rhythm, pacing leads, or mode.
年龄≥85岁的超高龄患者植入缓慢性心律失常起搏器(PM)后的预后尚不清楚。
我们回顾性纳入了868例患者(男性占49.0%,年龄76.6±10.6岁),这些患者能够独立行走且预期寿命超过1年,于2006年1月1日至2013年6月30日期间首次植入缓慢性心律失常PM。比较了超高龄患者(n = 201,平均年龄88.6±3.2岁)和年轻患者(n = 667,73.0±9.3岁)的临床结局。
在中位1285天的随访结束时,128例患者(14.7%)死亡,其中54例为心源性死亡(42.2%)。两组间的死亡率相似(16.4%对14.2%,对数秩检验p = 0.56),且在不同植入适应证(房室传导阻滞或病态窦房结综合征,p = 0.59)、初始心律(窦性心律或持续性心房颤动,p = 0.62)、起搏模式(双腔起搏或VVI起搏,p = 0.26)以及心室导线位置(间隔或心尖,p = 0.52)方面也是如此。在Cox比例风险模型分析中,高血压[风险比(HR)= 1.74,95%置信区间(CI)= 1.19 - 2.54,p = 0.004]、糖尿病(HR = 2.18,95% CI = 1.51 - 3.14,p < 0.001)、心肌梗死病史(HR = 3.59,95% CI = 2.49 - 5.16,p < 0.001)和卒中病史(HR = 2.26,95% CI = 1.51 - 3.37,p < 0.001)是死亡的独立预测因素。
在植入PM时无严重疾病且健康状况足以独立行走的超高龄患者的死亡率并不低于年轻患者。预后由合并症决定,而非年龄、PM适应证、初始心律、起搏导线或模式。